Idera Pharmaceuticals to Present Positive Phase 1 Trial Results on TLR
Antagonist IMO-8400 for the Treatment of Autoimmune Diseases at FOCIS 2013
CAMBRIDGE, Mass. -- June 21, 2013
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced that it will
present positive Phase 1 trial results on IMO-8400, a selective inhibitor of
Toll-like receptors (TLRs) 7, 8 and 9 and a lead candidate for the treatment
of autoimmune diseases, at the 13^th Annual Meeting of the Federation of
Clinical Immunology Societies (FOCIS), June 27-30, 2013, in Boston, MA.
Details of the presentation are as follows:
Date: Saturday, June 29, 2013
Time: 6:30-7:45pm ET
Location: Commonwealth Hall, The Boston Seaport Hotel
Abstract Number: S.85
Title: Phase 1 clinical trial of IMO-8400, an antagonist of
Toll-like receptors 7, 8 and 9
About Idera Pharmaceuticals, Inc.
Idera Pharmaceuticals applies its proprietary Toll-like receptor (TLR) drug
discovery platform to create immunomodulatory drug candidates and has a
clinical development program in autoimmune diseases. Additionally, Idera has a
collaboration with Merck & Co. for the use of TLR-targeted candidates as
vaccine adjuvants for cancer, infectious diseases and Alzheimer’s disease. For
more information, visit http://www.iderapharma.com.
Idera Pharmaceuticals, Inc.
Lou Arcudi, 617-679-5517
Press spacebar to pause and continue. Press esc to stop.